pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioSpace·34m ago·1 min read
save

CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapy

Nov 17, 2026·read at BioSpace ↗

At the 2026 Clinical Trials on Alzheimer’s Disease conference, AriBio reported that AR1001 slowed cognitive decline more than placebo in patients not taking other drugs for the disease.

source

Reporting by BioSpace.

read at BioSpace ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • just nowAstraZeneca, Calidi, Tempest make significant workforce cutsBioSpace
  • 58m agoSellas’ cancer vaccine slashes death risk by 41% in late-stage AML studyBioSpace
  • 1h agoLilly pens another deal, inking up to $5.9B oncology pact with StippleBioSpace
  • 2h agoGenetix’s genetic medicines are officially profitable, with $327M in sales YTDBioSpace
  • 3h agoMarrow Therapeutics debuts with $173M to tackle blood disorders in vivoBioSpace